Aurobindo Pharma Limited Technical Analysis

Name : Aurobindo Pharma Limited
NSE Symbol : AUROPHARMA | BSE Code : 524804
Sector : Pharmaceuticals

Dear Investors,

Aurobindo Pharma Limited was established in 1986 and is headquartered in Hyderabad Telangana. It is an integrated pharmaceutical company engaged in developing manufacturing and marketing generic medicines branded formulations and active pharmaceutical ingredients. Its portfolio covers therapeutic areas including antibiotics cardiovascular medicines central nervous system treatments and anti-retroviral products. Revenue is generated through domestic sales and exports across more than 150 countries. Growth opportunities include complex generics product launches and expansion in regulated international markets.

Market trend :

On 13 November 2026 the stock opened at ₹1800.10 against the previous close of ₹1807.20 and traded between ₹1800.10 and ₹1832.40. Available market updates during the session showed the share price moving above the previous close. A verified final closing price and corresponding Nifty 50 comparison were not available in the retrieved data; therefore a definitive statement on full-session outperformance and closing momentum cannot be made. The available intraday range indicates price fluctuation within a relatively narrow band.

Financial Performance :

For FY2026 the company reported consolidated revenue from operations of approximately ₹33653 crore compared with ₹31724 crore in FY2025, indicating growth of around 6.1%. Its business benefits from a diversified international presence and a broad portfolio of formulations and APIs. Performance remains influenced by product mix foreign-exchange movements regulatory compliance costs and pricing conditions in key export markets.

In Q2FY27 revenue reached ₹10263 crore up 23.9% year-on-year while EBITDA before forex and other income rose 28.5% to ₹2156 crore. EBITDA margin improved to 21.0% from 20.3% and net profit increased 32.5% to ₹1124 crore. US and European formulations contributed to growth. The latest available intraday market updates showed trading volume rising during the session; final full-day volume and official closing price require exchange confirmation.

Technical Analysis :

The reported 52-week range was ₹1106.00–₹1859.90. Available price updates placed the share above its 50-day and 200-day moving averages, indicating a positive broader price structure. However, exact Fibonacci levels Gann angles MACD RSI Bollinger Bands ADX and Stochastic RSI readings were not independently verified for the analysis date. VWAP data varied by timestamp. The stock’s proximity to its 52-week high may indicate sustained buying interest but also warrants attention to volatility and profit-taking.

Effecting Factors :

The company’s outlook is linked to global pharmaceutical demand USFDA approvals generic-drug pricing and currency movements. Domestic market direction India VIX and institutional flows can influence short-term trading. Company-specific developments include Q2FY27 revenue growth across US Europe and growth markets and the acquisition of Lannett which expands its US presence. Investors may also monitor R&D spending product launches regulatory observations debt levels margins return ratios and promoter shareholding disclosures.

Risk factor :

Key risks include regulatory observations or manufacturing compliance issues product recalls pricing pressure in the US generic market and delays in product approvals. Currency fluctuations supply-chain disruptions and rising research costs may affect profitability. International expansion and acquisitions also carry execution and integration risks.

Recommendation : Neutral Editorial Assessment – No Buy / Sell / Hold Recommendation.

Analysis Date : 13 November 2026 | Friday